Drug intelligence / Profile preview

Idomarine

Development stage: Unknown
Lead developer: MTI Medical
Modality: Small Molecules
Administration: Oral

Overview

Idomarine is a patented iodine polymer complex developed by MTI Medical for the management of polycystic ovary syndrome (PCOS), infertility, and related hormonal disorders. It is designed to modulate the thyroid-ovarian axis and interacts with the sodium-iodide symporter (NIS), peroxisome proliferator-activated receptor gamma (PPARγ), and estrogen receptors. By addressing subclinical hypothyroidism and hormonal imbalances, Idomarine aims to restore ovulatory function and treat conditions such as ovarian cysts, fibrocystic breast disease, hormonal acne, and hirsutism. It is approved by the Drug Regulatory Authority of Pakistan (DRAP) and is marketed as a nutraceutical solution for endocrine regulation.

Brand names: Idomarine
Other names: iodine polymer complex

Targets

NIS (Human sodium iodide symporter)

Beyond the preview

Go deeper on Idomarine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idomarine.

Explore the full profile